CEO Evan Sussman Featured in Boston Globe Article: Medication madness, increasing involvement of private equity — why IVF costs so much, and how it may get worse

Written By Sarah Faranda

Granata Bio’s CEO, Evan Sussman, worked with The Boston Globe to highlight how a lack of innovation in reproductive health has negatively impacted affordability in IVF treatments, and how Granata Bio and others are working to make infertility medications more accessible for those on the path to parenthood.

In the article, author Jessica Bartlett says, "In the most expensive classes of IVF drugs, there hasn’t been innovation in 20 years. Evan Sussman [and Granata Bio are] trying to change that."

Read the full article here.

Sarah Faranda
Previous

Granata Bio Corporation and Georgetown Equity Partners Announce Joint Venture to Develop a Novel, Next-Generation Form of Follicle-Stimulating Hormone (FSH)
Next

Granata Bio Announces Strategic Investment and Collaboration with Gedeon Richter to Expand U.S. Fertility Market Leadership